HC Wainwright Estimates Rezolute’s Q1 Earnings (NASDAQ:RZLT)

Rezolute, Inc. (NASDAQ:RZLT) – Equities research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Rezolute in a research report issued on Thursday, September 18th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($0.27) for the quarter. HC Wainwright currently has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.20) EPS, FY2027 earnings at ($1.20) EPS, FY2028 earnings at ($0.64) EPS and FY2029 earnings at ($0.46) EPS.

Several other brokerages have also recently commented on RZLT. Maxim Group raised their price objective on shares of Rezolute from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. Guggenheim restated a “buy” rating and set a $15.00 target price on shares of Rezolute in a report on Monday. Wedbush restated an “outperform” rating and set a $12.00 target price on shares of Rezolute in a report on Thursday, September 18th. Finally, BTIG Research restated a “buy” rating and set a $17.00 target price on shares of Rezolute in a report on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $14.50.

Rezolute Stock Up 4.7%

Shares of NASDAQ RZLT opened at $8.52 on Monday. Rezolute has a 52 week low of $2.21 and a 52 week high of $8.81. The firm has a 50-day moving average price of $6.75 and a 200 day moving average price of $4.80. The stock has a market capitalization of $773.70 million, a price-to-earnings ratio of -8.78 and a beta of 0.03.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Wednesday, September 17th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.03).

Institutional Investors Weigh In On Rezolute

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Pale Fire Capital SE grew its holdings in shares of Rezolute by 4.2% during the second quarter. Pale Fire Capital SE now owns 49,122 shares of the company’s stock worth $219,000 after buying an additional 2,000 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Rezolute by 5.2% during the first quarter. American Century Companies Inc. now owns 67,925 shares of the company’s stock worth $197,000 after buying an additional 3,334 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Rezolute during the second quarter worth about $25,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Rezolute during the second quarter worth about $30,000. Finally, Legal & General Group Plc purchased a new stake in shares of Rezolute during the second quarter worth about $32,000. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.